Cargando…
Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma
BACKGROUND: A synergy between radiotherapy and anti-cytotoxic-T-lymphocyte-associated antigen 4 (anti-CTLA-4) monoclonal antibody has been demonstrated preclinically. The Mel-Ipi-Rx phase 1 study aimed to determine the maximum tolerated dose (MTD) and safety profile of radiotherapy combined with ipi...
Autores principales: | Boutros, Celine, Chaput-Gras, Nathalie, Lanoy, Emilie, Larive, Alicia, Mateus, Christine, Routier, Emilie, Sun, Roger, Tao, Yun Gan, Massard, Christophe, Bahleda, Rastilav, Schwob, Dominique, Ibrahim, Nathalie, Khoury Abboud, Rita Maria, Caramella, Caroline, Lancia, Andrea, Cassard, Lydie, Roy, Severine, Soria, J -C, Robert, Caroline, Deutsch, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443273/ https://www.ncbi.nlm.nih.gov/pubmed/32819972 http://dx.doi.org/10.1136/jitc-2020-000627 |
Ejemplares similares
-
Radiomics to predict outcomes and abscopal response of patients with cancer treated with immunotherapy combined with radiotherapy using a validated signature of CD8 cells
por: Sun, Roger, et al.
Publicado: (2020) -
CD8(+)PD-1(+) to CD4(+)PD-1(+) ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
por: Duchemann, Boris, et al.
Publicado: (2022) -
IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatment
por: Desbois, Mélanie, et al.
Publicado: (2020) -
Estimating causal effects of time-dependent exposures on a binary endpoint in a high-dimensional setting
por: Asvatourian, Vahé, et al.
Publicado: (2018) -
Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
por: Koguchi, Yoshinobu, et al.
Publicado: (2021)